The Impact of Kidney Function on the Slow-Flow/No-Reflow Phenomenon in Patients Treated with Primary Percutaneous Coronary Intervention: Registry Analysis

Table 2

Therapy during hospitalization and at discharge from hospital.

	TIMI = 3	Slow-flow/no-reflow	value
In-hospital	N = 2969	N = 146
Aspirin, n (%)	2969 (100)	145 (99.99)	0.785
Clopidogrel, n (%)	2967 (99.99)	142 (97)	0.870
Heparin, n (%)	2554 (86.7)	146 (100)	0.009
Beta blockers, n (%)	2583 (87)	109 (75)	0.504
ACE inhibitors, n (%)	2211 (74.5)	92 (63.1)	0.001
Statin, n (%)	2227 (74.7)	107 (73.3)	0.145
Diuretics, n (%)	292 (13.2)	66 (45.5)	<0.001
At discharge	N = 2882	N = 102
Aspirin, n (%)	2882 (100)	102 (100)	0.955
Clopidogrel, n (%)	2850 (98.89)	92 (90.25)	0.552
Beta blockers, n (%)	2496 (86.7)	65 (63.7)	<0.001
ACE inhibitors, n (%)	2124 (73.7)	48 (47.1)	<0.001
Statins, n (%)	2880 (99.9)	100 (98.1)	0.985
Diuretic, n (%)	205 (6.9)	46 (45.5)	<0.001

number of discharged patients.